The FDA has approved Sarclisa (isatuximab) in combination with bortezomib, lenalidomide, and dexamethasone for transplant-ineligible, newly diagnosed multiple myeloma.
US FDA approves anti-CD38 therapy, Sarclisa in combo with standard-of-care treatment for adult patients with NDMM who are not eligible for transplant: Paris Tuesday, September 24, ...
Common adverse events (AEs) among patients with early stage breast cancer include laboratory abnormalities, decreased lymphocytes, leukocytes, neutrophils, hemoglobin, and decreased platelet.
Only very small amounts are needed, unlike other minerals such as calcium or magnesium. Essential in the formation of leukocytes, lymphocytes, and neutrophils, as well as in the phagocytosis process ...
Approval based on positive results from the IMROZ phase 3 study demonstrating Sarclisa in combination with bortezomib, lenalidomide, and dexamethasone (VRd) significantly improved progression-free ...
AbbVie (NYSE: ABBV) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the marketing ...